Multiple additional BCR-ABL TKIs are currently in development including bafetinib which has shown activity in imatinib-resistant CML, high grade gliomas and prostate cancer [11,12], and radotinib which was approved in Korea in 2015 as first line therapy for CML [13]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.